{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"},{"groupId":"OG001","value":"17.1"},{"groupId":"OG002","value":"38.1"},{"groupId":"OG003","value":"27.8"}]}],"title":"Neutrophil Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"8.6"},{"groupId":"OG002","value":"42.9"},{"groupId":"OG003","value":"5.6"}]}],"title":"White Blood Cell Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.6"}]}],"title":"Lymphocyte Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"2.9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.6"}]}],"title":"Aspartate Aminotransferase Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.6"}]}],"title":"Alanine Aminotransferase Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Bilirubin Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Hepatic Enzyme Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4.8"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Creatinine Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Creatinine Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Urea Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Chloride Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Sodium Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.7"},{"groupId":"OG002","value":"4.8"},{"groupId":"OG003","value":"0"}]}],"title":"Platelet Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"5.7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Alkaline Phosphatase Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Uric Acid Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Glucose Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Blood Albumin Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Protein Total Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Haematocrit Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Red Blood Cell Count Decreased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"Clinical laboratory tests included hematology, clinical chemistry and urinalysis. The investigator determined if the results were clinically significant. Only those categories were reported which are clinically significant at post Baseline.","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG000","title":"Pancreatic Cancer Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.","id":"OG001","title":"Metastatic CRC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG002","title":"sqEC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.","id":"OG003","title":"sqNSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set included all participants who received any amount of study drug. As pre-specified in the protocol, this outcome measure evaluated and reported data for participants only in the Tumor-Specific Cohorts.","reportingStatus":"POSTED","timeFrame":"From first dose of the study drug up to 30 days after the last dose (Up to approximately 15 months)","title":"Percentage of Participants With Clinically Significant Changes in Laboratory Values, Reported as Adverse Events in Tumor-Specific Cohorts","type":"SECONDARY","unitOfMeasure":"percentage of participants"}